Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated February 17, 2026, reports on a material update to a securities purchase agreement entered into by Clearmind Medicine Inc. on September 17, 2025. The filing addresses the issuance of convertible promissory notes to specific investors (CLA Investors) and a subsequent adjustment to the transaction terms based on the Company's current capital requirements and liquidity position.
Key Financial Metrics and Transaction Details
- Total Authorized Principal: Up to $10,000,000 under the original September 2025 agreement.
- Initial Notice Amount (Feb 4, 2026): $2,500,000 principal amount.
- Purchase Price: 90% of the principal amount (cash).
- Tranche 1 (Closed Feb 4, 2026): $600,000 principal; $540,000 cash proceeds.
- Tranche 2 (Revised): Reduced from $1,900,000 to $600,000 principal; $540,000 cash proceeds.
- Revised Total Proceeds for this Notice: $1,080,000 ($540,000 + $540,000).
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, or total debt levels outside of this specific transaction.
Material Changes
The primary material change is the reduction of the second tranche of the convertible promissory notes. Originally announced on February 4, 2026, the second tranche was set at $1,900,000 in principal. The Company has now reduced this amount to $600,000 in principal. All other terms of the second tranche remain unchanged.
Management Commentary and Outlook
Management stated that the reduction in the second tranche size was made "in light of its current capital requirements and liquidity position." The closing of the revised second tranche is contingent upon the filing of a registration statement covering the resale of common shares issuable upon conversion of the notes from both tranches.
Investor Verification Checklist
- Verify the final closing date and receipt of funds for the revised $600,000 second tranche.
- Confirm the filing status of the registration statement required for the resale of shares upon conversion.
- Review the Company's most recent audited financial statements to assess the impact of the reduced capital raise on overall liquidity.
- Check for any subsequent filings regarding the remaining $7,500,000 capacity under the original $10,000,000 agreement.